Tag Archives: Jay Olson

Oppenheimer Sticks to Their Buy Rating for TherapeuticsMD (TXMD)

Oppenheimer analyst Jay Olson reiterated a Buy rating on TherapeuticsMD (TXMD – Research Report) today and set a price target of $14. The company’s shares closed yesterday at $5.09. Olson noted: “TXMD reported 4Q results and launch progress for 2019

Oppenheimer Maintains a Buy Rating on CymaBay Therapeutics (CBAY)

Oppenheimer analyst Jay Olson maintained a Buy rating on CymaBay Therapeutics (CBAY – Research Report) today and set a price target of $18. The company’s shares closed yesterday at $9.77. Olson commented: “Seladelpar (PPARδ agonist) received Breakthrough Therapy Designation (BTD)

Incyte Corp (INCY) Gets a Hold Rating from Oppenheimer

In a report released today, Jay Olson from Oppenheimer reiterated a Hold rating on Incyte Corp (INCY – Research Report), with a price target of $85. The company’s shares opened today at $83.42. Olson observed: “INCY 4Q results were roughly

Oppenheimer Reaffirms Their Buy Rating on TherapeuticsMD (TXMD)

Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (TXMD – Research Report) yesterday and set a price target of $14. The company’s shares closed on Friday at $5.23. Olson observed: “TXMD provided an update on the Imvexxy launch

Oppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report), with a price target of $100. The company’s shares closed yesterday at $83.80. Olson commented: “ENTA reported 1QFY19 financial results,

Oppenheimer Sticks to Its Buy Rating for Neurocrine (NBIX)

Oppenheimer analyst Jay Olson reiterated a Buy rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $105. The company’s shares closed yesterday at $87.78. Olson observed: “With 4Q Ingrezza performance previously announced, NBIX provided a